The National Organization for Rare Disorders (NORD) announced two new requests for proposal (RFP) for grant funding related to Amyloidosis and Levy-Yeboa Syndrome (LYS). NORD’s Rare Disease Research Grant Program, established in 1989, provides seed money to qualified investigators for scientific and clinical research of diseases for which there are few other sources of funding.
- NORD, with donations from the amyloidosis community, is accepting applications for one grant of up to $45,000 US for scientific and/or clinical research studies related to amyloidosis. The deadline for applications is November 25, 2024 at 11:59 p.m. PT. Learn more and view application instructions here.
- NORD, with fundraising by the Maxwell Family, is accepting applications for one grant of up to $40,000 US for scientific and/or clinical research studies related to Levy-Yeboa syndrome (LYS). The deadline for applications is November 25, 2024 at 11:59 p.m. PT. Learn more and view application instructions here.
Grants will be awarded to qualified researchers to initiate small scientific research studies or clinical trials, the results of which could be used to obtain funding from the NIH, FDA, or other funding agencies, or to attract a corporate sponsor. Ideally, the proposed research should have the potential to lead to the development of a new or better therapy.
To learn more or submit to the 2024 NORD Research Grants Cycle, visit the Rare Disease Research Grant Program page of the NORD website.
About the National Organization for Rare Disorders (NORD)
With a more than 40-year history of advancing care, treatments and policy, the National Organization for Rare Disorders (NORD) is the leading and longest-standing patient advocacy group for the more than 30 million Americans living with a rare disease. An independent 501(c)(3) nonprofit, NORD is dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with its more than 340 patient organization members, is committed to improving the health and well-being of people with rare diseases by driving advances in care, research and policy.
